Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KARYOPHARM THERAPEUTICS INC.

(KPTI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Karyopharm Therapeutics : Partner Antengene Says Cancer Drug Xpovio Gets Approval in South Korea

08/02/2021 | 04:27am EDT


© MT Newswires 2021
All news about KARYOPHARM THERAPEUTICS INC.
10/12KARYOPHARM THERAPEUTICS : Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics t..
MT
10/01KARYOPHARM THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
09/13KARYOPHARM THERAPEUTICS : Corporate Presentation Sept 2021
PU
09/07KARYOPHARM THERAPEUTICS : Announces Upcoming Virtual Investor Conference Participation
PR
09/02KARYOPHARM THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
09/01KARYOPHARM THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
08/06KARYOPHARM THERAPEUTICS : Downgraded to Sector Perform From Outperform by RBC, Price Targe..
MT
08/06KARYOPHARM THERAPEUTICS : Baird Adjusts Karyopharm Therapeutics' Price Target to $17 From ..
MT
08/06KARYOPHARM THERAPEUTICS : Barclays Cuts Karyopharm Therapeutics' Price Target to $10 From ..
MT
08/06KARYOPHARM THERAPEUTICS : Morgan Stanley Adjusts Price Target for Karyopharm Therapeutics ..
MT
More news
Analyst Recommendations on KARYOPHARM THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 97,5 M - -
Net income 2021 -220 M - -
Net Debt 2021 40,2 M - -
P/E ratio 2021 -2,00x
Yield 2021 -
Capitalization 422 M 422 M -
EV / Sales 2021 4,74x
EV / Sales 2022 3,04x
Nbr of Employees 432
Free-Float 90,2%
Chart KARYOPHARM THERAPEUTICS INC.
Duration : Period :
Karyopharm Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARYOPHARM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,59 $
Average target price 15,00 $
Spread / Average Target 168%
EPS Revisions
Managers and Directors
Richard A. Paulson President, CEO & Non-Executive Director
Michael P. Mason Treasurer, Chief Financial & Accounting Officer
Sharon Shacham Chief Scientific Officer
Jatin Shah Chief Medical Officer & Executive Vice President
Yosef Landesman Senior VP-Research & Translational Medicine
Sector and Competitors
1st jan.Capi. (M$)
KARYOPHARM THERAPEUTICS INC.-63.89%422
GILEAD SCIENCES, INC.16.08%84 795
BIONTECH SE203.83%59 820
WUXI APPTEC CO., LTD.29.45%57 897
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156